
Claims

1. A drug conjugate comprising a drug moiety covalently attached to the rest of the drug conjugate, the drug conjugate having formula $[D-(X)_b-(AA)_w-(T)_g-(L)-]_n-Ab$ wherein:

D is a drug moiety having the following formula **(I)** or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof,



(I)

wherein:

D is covalently attached via a hydroxy or amine group to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or (L);

Y is -NH- or -O-;

R_1 is -OH or -CN;

R_2 is a $-C(=O)R_a$ group;

R_3 is hydrogen or a $-OR_b$ group;

R_4 is selected from hydrogen, $-CH_2OH$, $-CH_2OC(=O)R_c$, $-CH_2NH_2$, and $-CH_2NHProt^{NH}$;

R_a is selected from hydrogen, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl;

R_b is selected from substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl;

R_c is selected from substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl; and

$Prot^{NH}$ is a protecting group for amino;

X and T are extending groups that may be the same or different;

each AA is independently an amino acid unit;

L is a linker group;

w is an integer ranging from 0 to 12;

b is an integer of 0 or 1;


g is an integer of 0 or 1;

Ab is a moiety comprising at least one antigen binding site; and

n is the ratio of the group [D-$(X)_b$-$(AA)_w$-$(T)_g$-(L)-] to the moiety comprising at least one antigen binding site and is in the range from 1 to 20.

2. ~~A~~ The drug conjugate according to claim 1 comprising a drug moiety covalently attached to the rest of the drug conjugate, the drug conjugate having formula [D-$(X)_b$-$(AA)_w$-$(T)_g$-(L)-]$_n$-Ab wherein:

D is a drug moiety having the following formula **(IH)** or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof,



(IH)

wherein:

the wavy line indicates the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to (L);

Y is -NH- or -O-;

R_1 is -OH or -CN;

R_2 is a -C(=O)R_a group;

R_3 is hydrogen or a -OR_b group;

R_4 is selected from hydrogen, -CH_2OH, -CH_2OC(=O)R_c, -CH_2NH_2, and -CH_2NHProt^{NH};

R_a is selected from hydrogen, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl;

R_b is selected from substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl;

R_c is selected from substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl; and

Prot^{NH} is a protecting group for amino;

X and T are extending groups that may be the same or different;

each AA is independently an amino acid unit;

L is a linker group;

w is an integer ranging from 0 to 12;

b is an integer of 0 or 1;

g is an integer of 0 or 1;

Ab is a moiety comprising at least one antigen binding site; and

n is the ratio of the group $[D-(X)_b-(AA)_w-(T)_g-(L)-]$ to the moiety comprising at least one antigen binding site and is in the range from 1 to 20.

~~3. The drug conjugate according to claim 1 or 2, wherein R_4 is selected from hydrogen, $-CH_2OH$, $-CH_2O(C=O)R_e$, and $-CH_2NH_2$ wherein R_e is substituted or unsubstituted C_1-C_6 alkyl.~~

~~4. The drug conjugate according to claim 3, wherein R_e is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted *n*-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted *n*-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted *sec*-butyl, and substituted or unsubstituted *tert*-butyl; preferably wherein R_e is methyl.~~

~~5. The drug conjugate according to claim 3 wherein R_4 is hydrogen, $-CH_2OH$ or $-CH_2NH_2$.~~

~~6. The drug conjugate according to claim 5, wherein R_4 is hydrogen or $-CH_2OH$.~~

~~7. The drug conjugate according to claim 6, wherein R_4 is hydrogen.~~

~~8. The drug conjugate according to any preceding claim, wherein Y is $-NH-$.~~

~~9. The drug conjugate according to any one of claims 1 to 7, wherein Y is $-O-$.~~

~~10. The drug conjugate according to any preceding claim, wherein R_1 is $-OH$.~~

~~11. The drug conjugate according to any one of claims 1 to 9, wherein R_1 is $-CN$.~~

~~12. The drug conjugate according to any preceding claim, wherein R_2 is a $-C(=O)R_a$ group where R_a is substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_a is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted *n*-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted *n*-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted *sec*-butyl and substituted or unsubstituted *tert*-butyl.~~

~~13. The drug conjugate according to claim 12 wherein R_2 is acetyl.~~

~~14. The drug conjugate according to any preceding claim, wherein R_3 is hydrogen or $-OR_b$ wherein R_b is substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_b is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted *n*-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted *n*-~~


~~butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted *sec* butyl and substituted or unsubstituted *tert* butyl.~~

~~15. The drug conjugate according to claim 14 wherein R_3 is hydrogen.~~


~~16. The drug conjugate according to claim 14 wherein R_3 is $-OR_b$ wherein R_b is substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_b is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted *n* propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted *n* butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted *sec* butyl and substituted or unsubstituted *tert* butyl.~~

~~17. The drug conjugate according to claim 16 wherein R_3 is methoxy.~~

~~18. The drug conjugate according to claim 1, wherein D is a compound of formula:~~




~~and~~



~~,~~

~~or a pharmaceutically acceptable salt or ester thereof;~~


~~19~~3. The drug conjugate according to claim ~~18~~1, wherein D is a compound of formula:



,

or a pharmaceutically acceptable salt or ester thereof.

~~20~~4. The drug conjugate according to claim ~~18~~1, wherein D is a compound of formula:




,

or a pharmaceutically acceptable salt or ester thereof.

~~21~~5. The drug conjugate according to any one of claims 1 to ~~20~~4, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, *p*-toluenesulfonate, sodium, potassium, calcium, ammonium, ethylenediamine, ethanolamine, *N*,*N*-dialkylenethanolamine, triethanolamine and basic aminoacids.

~~22~~6. ~~A~~ The drug conjugate according to any one of the preceding claims, wherein L is a linker group selected from the group consisting of:



wherein

the wavy lines indicate the point of covalent attachments to an Ab (the wavy line to the right) and to $(T)_g$ if any, or $(AA)_w$ if any, or $(X)_b$ if any, or D (the wavy line to the left);

R_{19} is selected from -C_1-C_{12} alkylene-, -C_3-C_8 carbocyclo, -O-(C_1-C_{12} alkylene), -C_6-C_{18} arylene in one or more rings which may optionally be substituted with one or more substituents R_x, -C_1-C_{12} alkylene-C_6-C_{18} arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, -C_6-C_{18} arylene-C_1-C_{12} alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, -C_1-C_{12} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{12} alkylene-, -C_5-C_{14} heterocyclo- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -C_1-C_{12} alkylene-(C_5-C_{14} heterocyclo)- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -(C_5-C_{14} heterocyclo)-C_1-C_{12} alkylene- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -$(OCH_2CH_2)_r$- and -CH_2-$(OCH_2CH_2)_r$-, wherein

each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;

R_{30} is a -C_1-C_6 alkylene- group;

M is selected from the group consisting of -C_1-C_6 alkylene-, -C_1-C_6 alkylene-(C_3-C_8 carbocyclo)-, -$(CH_2CH_2O)_s$-, -C_1-C_6 alkylene-(C_3-C_8 carbocyclo)-CON(H or C_1-C_6 alkyl)-C_1-C_6 alkylene-, phenylene which may optionally be substituted with one or more substituents R_x, phenylene-C_1-C_6 alkylene- wherein the phenylene moiety may optionally be substituted with one or more substituents R_x and -C_1-C_6 alkylene-CON(H or C_1-C_6 alkyl)C_1-C_6 alkylene-;


Q is selected from the group consisting of -N(H or C_1-C_6 alkyl)phenylene- and -N(H or C_1-C_6 alkyl)-$(CH_2)_s$;

r is an integer ranging from 1 to 10; and

s is an integer ranging from 1 to 10~~.~~;

or

~~23. A drug conjugate according to any of claims 1 to 22,~~ wherein L is a linker group selected from the group consisting of:



wherein:

the wavy lines indicate the point of covalent attachments to an Ab (the wavy line to the right) and to $(T)_g$ if any, or $(AA)_w$ if any, or to $(X)_b$ (the wavy line to the left);


R_{19} is selected from -C_1-C_{12} alkylene-, -O-(C_1-C_{12} alkylene), -C_6-C_{12} arylene in one or more rings which may optionally be substituted with one or more substituents R_x, -C_1-C_{12} alkylene-C_6-C_{12} arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, -C_6-C_{12} arylene-C_1-C_{12} alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, -C_5-C_{12} heterocyclo- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -C_1-C_{12} alkylene-(C_5-C_{12} heterocyclo)- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -(C_5-C_{12} heterocyclo)-C_1-C_{12} alkylene- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -$(OCH_2CH_2)_r$- and -CH_2-$(OCH_2CH_2)_r$-, wherein each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;

R_{30} is a -C_1-C_6 alkylene- group;


M is selected from the group consisting of -C_1-C_6 alkylene-, -C_1-C_6 alkylene-(C_3-C_8 carbocyclo)- and phenylene which may optionally be substituted with one or more substituents R_x; and

r is an integer ranging from 1-6.


~~24~~7. ~~A~~ The drug conjugate according to any one of claims 1 to ~~23~~6, selected from the formulas (IV), (V) and (VI):



(IV)



(V)



(VI)

wherein:

X and T are extending groups that may be the same or different;

each AA is independently an amino acid unit;

w is an integer ranging from 0 to 12;

b is an integer of 0 or 1;

g is an integer of 0 or 1;

D is a drug moiety;

Ab is a moiety comprising at least one antigen binding site;

n is the ratio of the group [D-($X)_b$-($AA)_w$-($T)_g$-(L)-] wherein L is as defined in formula (IV), (V) or (VI) to the moiety comprising at least one antigen binding site and is in the range from 1 to 20;


R_{19} is selected from -C_1-C_8 alkylene-, -O-(C_1-C_8 alkylene), -C_1-C_8 alkylene-C_6-C_{12} arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, and -C_6-C_{12} arylene-C_1-C_8 alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, wherein each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;

R_{30} is a -C_2-C_4 alkylene- group; and


M is selected from the group consisting of -C_1-C_3 alkylene- and -C_1-C_3 alkylene-(C_5-C_7 carbocyclo)-;

or.


~~25. A drug conjugate according to claim 24~~ selected from the formulas (IV), (V) and (VI):



(IV)



(V)



(VI)

wherein:

X and T are extending groups that may be the same or different;

each AA is independently an amino acid unit;

w is an integer ranging from 0 to 12;

b is an integer of 0 or 1;

g is an integer of 0 or 1;

D is a drug moiety;

Ab is a moiety comprising at least one antigen binding site;


n is the ratio of the group [D-$(X)_b$-$(AA)_w$-$(T)_g$-(L)-] wherein L is as defined in (IV), (V) or (VI) to the moiety comprising at least one antigen binding site and is in the range from 1 to 20;

R_{19} is selected from -C_1-C_6 alkylene-, phenylene-C_1-C_6 alkylene- wherein the phenylene group may optionally be substituted with one or more substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, wherein each of the above alkylene substituents whether alone or attached to another moiety in the carbon chain may optionally be substituted by one or more substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, aryl groups having from 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups, and preferably R_{19} is a -C_1-C_6 alkylene group;

R_{30} is a -C_2-C_4 alkylene- group; and

M is -C_1-C_3 alkylene-(C_5-C_7 carbocyclo)-.


~~26~~8. The ~~A~~ drug conjugate according to any one of claims 1 to ~~25~~7, wherein $(AA)_w$ is of formula (II):



(II)

wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right); and

R_{21} is, at each occurrence, selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, $-CH_2OH$, $-CH(OH)CH_3$, $-CH_2CH_2SCH_3$, $-CH_2CONH_2$, $-CH_2COOH$, $-CH_2CH_2CONH_2$, $-CH_2CH_2COOH$, $-(CH_2)_3NHC(=NH)NH_2$, $-(CH_2)_3NH_2$, $-(CH_2)_3NHCOCH_3$, $-(CH_2)_3NHCHO$, $-(CH_2)_4NHC(=NH)NH_2$, $-(CH_2)_4NH_2$, $-(CH_2)_4NHCOCH_3$, $-(CH_2)_4NHCHO$, $-(CH_2)_3NHCONH_2$, $-(CH_2)_4NHCONH_2$, $-CH_2CH_2CH(OH)CH_2NH_2$, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl,



and w is an integer ranging from 0 to 12~~.~~;

or

~~27. A drug conjugate according to claim 26,~~ wherein $(AA)_w$ is of formula (II) wherein:


R_{21} is selected, at each occurrence, from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, $-(CH_2)_3NHCONH_2$, $-(CH_2)_4NH_2$,

$-(CH_2)_3NHC(=NH)NH_2$ and $-(CH_2)_4NHC(=NH)NH_2$; and

w is an integer ranging from 0 to 6~~.~~;

or

~~28. A drug conjugate according to any one of claims 1 to 26,~~ wherein w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):



(III)

wherein:

the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right);

R_{22} is selected from methyl, benzyl, isopropyl, *sec*-butyl and indolylmethyl; and

R_{23} is selected from methyl, $-(CH_2)_4NH_2$, $-(CH_2)_3NHCONH_2$ and $-(CH_2)_3NHC(=NH)NH_2$.

~~299~~. The ~~A~~ drug conjugate according to any one of claims 1 to ~~288~~, wherein X is an extending group selected from:

where D is covalently attached via an amine group:

-COO-(C_1-C_6 alkylene)NH-;

-COO-CH_2-(phenylene which may optionally be substituted with one or more substituents R_x)-NH-;

-COO-(C_1-C_6 alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with one or more substituents R_x)-NH-;

-$COCH_2NH$-$COCH_2$-NH-;

-$COCH_2NH$-;

-COO-(C_1-C_6 alkylene)S-;

-COO-(C_1-C_6 alkylene)NHCO(C_1-C_6 alkylene)S-; and

where D is covalently attached via an hydroxy group:

-CONH-(C_1-C_6 alkylene)NH-;

-COO-CH_2-(phenylene which may optionally be substituted with one or more substituents R_x)-NH-;

-CONH-(C_1-C_6 alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with one or more substituents R_x)-NH-;

-$COCH_2NH$-$COCH_2$-NH-;

-$COCH_2NH$-;

-CONH-(C_1-C_6 alkylene)S-;

-CONH-(C_1-C_6 alkylene)NHCO(C_1-C_6 alkylene)S-; and

b is 0 or 1, preferably 1~~.~~

or

~~30. A drug conjugate according to any one of claims 1 to 29,~~ wherein X is an extending group selected from the group consisting of:

where D is covalently attached via an amine group:

-COO-(C_2-C_4 alkylene)NH-;

-COO-CH_2-phenylene-NH-, wherein said phenylene group may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups;

-COO-(C_2-C_4 alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-;

-$COCH_2NH$-$COCH_2$-NH-;

-COO-(C_2-C_4 alkylene)S-;

-COO-(C_2-C_4 alkylene)NHCO(C_1-C_3 alkylene)S-; or

where D is covalently attached via an hydroxy group:

-CONH-(C_2-C_4 alkylene)NH-;

-COO-CH_2-phenylene-NH-, wherein said phenylene group may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups;

-CONH-(C_2-C_4 alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-;

-$COCH_2NH$-$COCH_2$-NH-;

-CONH-(C_2-C_4 alkylene)S-;

-CONH-(C_2-C_4 alkylene)NHCO(C_1-C_3 alkylene)S-; and

b is 0 or 1, preferably 1~~.~~;

or

~~31. A drug conjugate according to claim 30,~~ wherein X is an extending group selected from the group consisting of:

where D is covalently attached via an amine group:

-COO-CH_2-phenylene-NH-

-$COO(CH_2)_3NHCOOCH_2$-phenylene-NH-;

-$COO(CH_2)_3NH$-;

-$COO(CH_2)_3$-S-;

-$COO(CH_2)_3NHCO(CH_2)_2S$-; or

where D is covalently attached via an hydroxy group:

-COO-CH_2-phenylene-NH-

-$CONH(CH_2)_3NHCOOCH_2$-phenylene-NH-;

-$CONH(CH_2)_3NH$-;

-$CONH(CH_2)_3$-S-;

-$CONH(CH_2)_3NHCO(CH_2)_2S$-; and

b is 0 or 1, preferably 1.

~~32~~10. The ~~A~~ drug conjugate according to any one of claims 1 to ~~31~~9, wherein T is an extending group selected from the group consisting of -CO-(C_1-C_6 alkylene)-NH-,-CO-(C_1-C_6 alkylene)-[O-(C_2-C_6 alkylene)]$_j$-NH-, -COO-(C_1-C_6 alkylene)-[O-(C_2-C_6 alkylene)]$_j$-NH-; where j is an integer from 1 to 25, and g is 0 or 1~~.~~;

or

~~33. A drug conjugate according to claim 32,~~ wherein T is an extending group selected from the group consisting of -CO-(C_1-C_4 alkylene)NH-, -CO-(C_1-C_4 alkylene)-[O-(C_2-C_4 alkylene)]$_j$-NH-, -COO-(C_1-C_4 alkylene)-[O-(C_2-C_4 alkylene)]$_j$-NH-,where j is an integer from 1 to 10; and g is 0 or 1~~.~~;

or

~~34. A drug conjugate according to claim 33,~~ wherein T is an extending group selected from the group consisting of -CO-(C_1-C_4 alkylene)NH-, -CO-(C_1-C_4 alkylene)-[O-(C_2-C_4 alkylene)]$_j$-NH-, -COO-(C_1-C_4 alkylene)-[O-(C_2-C_4 alkylene)]$_j$-NH-; where j is an integer from 1 to 5; and g is 0 or 1.

~~35~~11. A drug conjugate according to any preceding claim, wherein D is a drug moiety of formula **(IH)** or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein:

R_1 is CN or OH;

R_2 is C(=O)R_a, wherein R_a is selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl, wherein the optional substituents are one or more substituents R_x;

R_3 is hydrogen or a -OR_b group wherein R_b is a substituted or unsubstituted C_1-C_6 alkyl group, wherein the optional substituents are one or more substituents R_x,

R_4 is selected from hydrogen, -CH_2OH, and -CH_2NH_2; and

Y is -NH- or -O~~.~~;

or

~~36. A drug conjugate according to claim 35,~~ wherein D is a drug moiety of formula **(IH)** or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein:

R_1 is CN or OH;

R_2 is acetyl;

R_3 is hydrogen or methoxy, more preferably methoxy;

R_4 is hydrogen or $–CH_2OH$; and

Y is -NH- or -O~~-~~;

or

~~37. A drug conjugate according to claim 35 or claim 36~~ wherein D is a drug moiety of formula **(IH)**, or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof wherein:

R_1 is CN;


R_2 is acetyl:

R_3 is methoxy;


R_4 is hydrogen; and

Y is -NH- or -O-, preferably -NH-.

~~38~~12. The ~~A~~ drug conjugate according to any preceding claim, wherein D is selected from:



and



,

or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein the wavy line indicates the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to (L).

~~39~~13. The ~~A~~ drug conjugate according to any one of claims 1 to ~~38~~12, wherein the moiety Ab comprising at least one antigen binding site is an antigen-binding peptide~~.~~;

optionally

~~40. A drug conjugate according to claim 39,~~ wherein the moiety Ab comprising at least one antigen binding site is an antibody, a single domain antibody or an antigen-binding fragment thereof~~.~~;

optionally

41. A drug conjugate according to claim 39 or 40, wherein the moiety Ab comprising at least one antigen binding site is a monoclonal antibody, polyclonal antibody or bispecific antibody and wherein the antibody or an antigen-binding fragment thereof is derived from any species, preferably a human, mouse or rabbit.;

optionally

42. A drug conjugate according to claim 40 or 41, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a human antibody, an antigen-binding fragment of a human antibody, a humanized antibody, an antigen-binding fragment of a humanized antibody, a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a glycosylated antibody and a glycosylated antigen binding fragment.;

optionally

43. A drug conjugate according to any one of claims 40 to 42, wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')2 fragment and an Fv fragment.;

optionally

44. A drug conjugate according to any one of claims 40 to 43, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody which immunospecifically binds to cancer cell antigens, viral antigens, antigens of cells that produce autoimmune antibodies associated with autoimmune disease, microbial antigens, and preferably a monoclonal antibody which immunospecifically binds to cancer cell antigens.;

optionally

45. A drug conjugate according to any one of claims 1 to 44, wherein the moiety Ab comprising at least one antigen binding site is an antibody selected from the group consisting of Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Coltuximab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Lifastuzumab, Lorvotuzumab, Milatuzumab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Panitumumab, Pembrolizumab, Pertuzumab, Pinatuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Sofituzumab, Vadastuximab, Vorsetuzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof.;

optionally

46. A drug conjugate according to claim 45, wherein the moiety Ab comprising at least one antigen binding site is an antibody selected from the group consisting of Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab,


Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Panitumumab, Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Vadastuximab, Vorsetuzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof.;

optionally

47. A drug conjugate according to claim 45, wherein the moiety Ab comprising at least one antigen binding site is an antibody selected from the group consisting of Alemtuzumab, Atezolizumab, Avelumab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daratumumab, Denosumab, Dinutuximab, Durvalumab, Elotuzumab, Gemtuzumab, Ibritumomab, Inotuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuximab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, more preferably Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologicallly active portion thereof, preferably an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof, more preferably Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof.

48. A drug conjugate according to claim 2, wherein:

L is a linker group selected from the group consisting of:



wherein:

the wavy lines indicate the point of covalent attachments to an Ab (the wavy line to the right) and to $(T)_g$ if any, or $(AA)_w$ if any, or to $(X)_b$ if any, or to D (the wavy line to the left);

R_{19} is selected from C_1-C_{12} alkylene , O (C_1-C_{12} alkylene), C_6-C_{12} arylene in one or more rings which may optionally be substituted with one or more substituents R_x, C_1-C_{12} alkylene-C_6-C_{12} arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, C_6-C_{12} arylene-C_1-C_{12} alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, C_5-C_{12} heterocyclo- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, C_1-C_{12} alkylene (C_5-C_{12} heterocyclo)- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, (C_5-C_{12} heterocyclo)-C_1-C_{12} alkylene- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, $-(OCH_2CH_2)_r-$ and $-CH_2-(OCH_2CH_2)_r-$, wherein


each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;

R_{30} is a C_1-C_6 alkylene group;

M is selected from the group consisting of C_1-C_6 alkylene, C_1-C_6 alkylene (C_3-C_8 carbocyclo) and phenylene which may optionally be substituted with one or more substituents R_x;

r is an integer ranging from 1-6;


$(AA)_w$ is of formula (II):



(II)

wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right);

R_{21} is, at each occurrence, selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, $-CH_2OH$, $-CH(OH)CH_3$, $-CH_2CH_2SCH_3$, $-CH_2CONH_2$, $-CH_2COOH$, $-CH_2CH_2CONH_2$, $-CH_2CH_2COOH$, $-(CH_2)_3NHC(=NH)NH_2$, $-(CH_2)_3NH_2$, $-(CH_2)_3NHCOCH_3$, $-(CH_2)_3NHCHO$, $-(CH_2)_4NHC(=NH)NH_2$, $-(CH_2)_4NH_2$, $-(CH_2)_4NHCOCH_3$, $-(CH_2)_4NHCHO$, $-(CH_2)_3NHCONH_2$, $-(CH_2)_4NHCONH_2$, $-CH_2CH_2CH(OH)CH_2NH_2$, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, phenyl, cyclohexyl,



w is an integer ranging from 0 to 12;

wherein X is an extending group selected from

~~-COO-(C_1-C_6-alkylene)NH-, -COO-CH_2-(phenylene which may optionally be substituted with one or more substituents R_x)-NH-, -COO-(C_1-C_6-alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with one or more substituents R_x)-NH-, -$COCH_2NH$-$COCH_2$-NH-, -$COCH_2$-NH-, -COO-(C_1-C_6-alkylene)S-, -COO-(C_1-C_6-alkylene)NHCO(C_1-C_6 alkylene)S-;~~

~~b is 0 or 1, preferably 1;~~

~~wherein T is an extending group selected from -CO-(C_1-C_6-alkylene)-NH-, -CO-(C_1-C_6 alkylene)-[O-(C_2-C_6-alkylene)]$_j$-NH-, and -COO-(C_1-C_6-alkylene)-[O-(C_2-C_6-alkylene)]$_j$-NH-, where j is an integer from 1 to 25;~~

~~g is 0 or 1;~~

~~D is a drug moiety of formula (**III**), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof wherein:~~

~~R_1-CN or OH;~~

~~R_2 is C(=O)R_a, wherein R_a is selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl, wherein the optional substituents are one or more substituents R_x;~~

~~R_3 is hydrogen or a -OR_b group wherein R_b is a substituted or unsubstituted C_1-C_6 alkyl group, wherein the optional substituents are one or more substituents R_x;~~


~~R_4 is hydrogen, -CH_2OH or -CH_2NH_2;~~

~~Y is -NH- or -O-;~~


~~the moiety Ab comprising at least one antigen binding site is an antibody or an antigen-binding fragment thereof and it is selected from the group consisting of a human antibody, an antigen binding fragment of a human antibody, a humanized antibody, an antigen binding fragment of a humanized antibody, a chimeric antibody, an antigen binding fragment of a chimeric antibody, a glycosylated antibody and a glycosylated antigen binding fragment; and~~

~~n is the ratio of the group [D-$(X)_b$-$(AA)_w$-$(T)_g$-(L)-] to the moiety Ab comprising at least one antigen binding site and is in the range from 1 to 12.~~


~~49. A drug conjugate according to claim 2, selected from the formulas (IV), (V), and (VI):~~



(IV)



(V)



(VI)


~~wherein:~~

~~R_{19} is selected from $-C_1-C_8$ alkylene-, $-O-(C_1-C_8$ alkylene), $-C_1-C_8$ alkylene-C_6-C_{12} arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x and $-C_6-C_{12}$ arylene-C_1-C_8 alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x; wherein each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;~~

~~R_{30} is a $-C_2-C_4$ alkylene- group;~~

~~M is selected from the group consisting of $-C_1-C_3$ alkylene- and $-C_1-C_3$ alkylene-(C_5-C_7 carbocyclo)-;~~

~~$(AA)_w$ is of formula (II)~~



(II) ,

~~wherein:~~

~~the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right);~~

~~R_{21} is, at each occurrence, selected from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, $-(CH_2)_3NHCONH_2$, $-(CH_2)_4NH_2$, $-(CH_2)_3NHC(=NH)NH_2$ and $-(CH_2)_4NHC(=NH)NH_2$;~~

~~w is an integer from 0 to 6;~~

~~X is an extending group selected from the group consisting of~~

~~$-COO-(C_2-C_4$ alkylene)NH-, $-COO-CH_2$-phenylene-NH-, wherein said phenylene group may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, $-COO-(C_2-C_4$ alkylene)NH-~~

~~$COO-CH_2-$ (phenylene which may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups) $-NH-$, $-COCH_2NH-COCH_2-NH-$, $-COO-(C_2-C_4$ alkylene)$S-$, and $-COO-(C_2-C_4$ alkylene)$NHCO(C_1-C_3$ alkylene)$S-$;~~

~~b is 0 or 1, preferably 1;~~

~~wherein T is an extending group selected from $-CO-(C_1-C_4$ alkylene) $NH-$, $-CO-(C_1-C_4$ alkylene) $-[O-(C_2-C_4$ alkylene)$]_j-NH-$, and $-COO-(C_1-C_4$ alkylene) $-[O-(C_2-C_4$ alkylene)$]_j-NH-$, where j is an integer from 1 to 10;~~

~~g is 0 or 1;~~

~~D is a drug moiety of formula (**III**), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof wherein:~~

~~R_1 is CN or OH;~~

~~R_2 is acetyl;~~

~~R_3 is hydrogen or methoxy, more preferably methoxy;~~


~~R_4 is hydrogen or $-CH_2OH$;~~

~~Y is $-NH-$ or $-O-$;~~


~~the moiety Ab comprising at least one antigen binding site is an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen binding fragment is a monoclonal antibody which immunospecifically binds to cancer cell antigens, viral antigens, antigens of cells that produce autoimmune antibodies associated with autoimmune disease, microbial antigens, and preferably a monoclonal antibody which immunospecifically binds to cancer cell antigens; and~~

~~n is the ratio of the group $[D-(X)_b-(AA)_w-(T)_g-(L)-]$ wherein L is as defined in formulas (IV), (V) or (VI) to the moiety Ab comprising at least one antigen binding site and is in the range from 3 to 8.~~


~~50. A drug conjugate according to claim 2, selected from the formulas (IV), (V) and (VI):~~



(IV)



(V)



(VI)


~~wherein:~~

~~R_{19} is selected from -C_1-C_6 alkylene-, -phenylene-C_1-C_6 alkylene- wherein the phenylene group may optionally be substituted with one or more substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, wherein each of the above alkylene substituents whether alone or attached to another moiety in the carbon chain may optionally be substituted by one or more substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, aryl groups having from 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups, and preferably R_{19} is a C_1-C_6 alkylene group;~~

~~R_{30} is a -C_2-C_4 alkylene- group;~~

~~M is -C_1-C_3 alkylene (C_5-C_7 carbocyclo) ;~~

~~w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):~~



(III)

~~wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right);~~

~~R_{22} is selected from methyl, benzyl, isopropyl, *sec* butyl and indolylmethyl;~~

~~R_{23} is selected from methyl, $-(CH_2)_4NH_2$, $-(CH_2)_3NHCONH_2$ and $-(CH_2)_3NHC(=NH)NH_2$;~~

~~X is an extending group selected from the group consisting of -COO-(C_2-C_4 alkylene)NH-, -COO-CH_2-phenylene-NH-, wherein said phenylene group may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C_2-C_4 alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6~~

carbon atoms, halogen atoms, nitro groups or cyano groups) NH , $-COCH_2NH-COCH_2-NH$, $-COO-(C_2-C_4$ alkylene)S , and $-COO-(C_2-C_4$ alkylene)NHCO(C_1-C_3 alkylene)S ;

b is 0 or 1, preferably 1;

wherein T is an extending group selected from $-CO-(C_1-C_4$ alkylene) NH , $-CO-(C_1-C_4$ alkylene) $[O-(C_2-C_4$ alkylene)$]_j$ NH , and $-COO-(C_1-C_4$ alkylene) $[O-(C_2-C_4$ alkylene)$]_j$ NH , where j is an integer from 1 to 5;

g is 0 or 1;

D is a drug moiety of formula **(III)**, or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof wherein:

R_1 is CN;

R_2 is acetyl:

R_3 is methoxy;

R_4 is hydrogen;

Y is NH or O ;


the moiety Ab comprising at least one antigen binding site is a monoclonal antibody selected from the group consisting of Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Coltuximab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Lifastuzumab, Lorvotuzumab, Milatuzumab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Panitumumab, Pembrolizumab, Pertuzumab, Pinatuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Sofituzumab, Vadastuximab, Vorsetuzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof; preferably Alemtuzumab, Atezolizumab, Avelumab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daratumumab, Denosumab, Dinutuximab, Durvalumab, Elotuzumab, Gemtuzumab, Ibritumomab, Inotuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuximab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, more preferably Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, preferably an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof, more preferably Trastuzumab or an antigen-binding fragment or an immunologicallly active portion thereof; and

n is the ratio of the group $[D-(X)_b-(AA)_w-(T)_g-(L)-]$ wherein L is as defined in formulas (IV), (V) or (VI) to the moiety Ab comprising at least one antigen binding site and is in the range from 3 to 5.


51. A drug conjugate according to claim 50, the moiety Ab comprising at least one antigen binding site is an antibody selected from the group consisting of Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Panitumumab, Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Vadastuximab, Vorsetuzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof.

52. A drug conjugate according to claim 50, wherein the moiety Ab comprising at least one antigen binding site is an antibody selected from the group consisting of Alemtuzumab, Atezolizumab, Avelumab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daratumumab, Denosumab, Dinutuximab, Durvalumab, Elotuzumab, Gemtuzumab, Ibritumomab, Inotuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuximab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, more preferably Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, preferably an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof, more preferably Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof.


53. A drug conjugate according to claim 2, selected from the formulas (IV), (V) and (VI):



(IV)



(V)



(VI)


wherein:

R_{19} is C_2-C_6 alkylene ;

R_{30} is a C_2-C_4 alkylene ;

M is C_1-C_3 alkylene (C_5-C_7 carbocyclo) ;

w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):



(III)

,

wherein R_{22} is isopropyl, R_{23} is selected from methyl and $(CH_2)_3NHCONH_2$, wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right);


X is an extending group selected from the group consisting of -COO-(C_2-C_4-alkylene)NH-, -COO-CH_2-phenylene-NH-, wherein said phenylene group may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C_2-C_4-alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -$COCH_2$NH-$COCH_2$-NH-, -COO-(C_2-C_4-alkylene)S-, and -COO-(C_2-C_4-alkylene)NHCO(C_1-C_3-alkylene)S;

b is 0 or 1, preferably 1;


wherein T is an extending group selected from -CO-(C_1-C_4-alkylene)-NH-, -CO-(C_1-C_4-alkylene)-[O-(C_2-C_4-alkylene)]$_j$-NH-, and -COO-(C_1-C_4-alkylene)-[O-(C_2-C_4-alkylene)]$_j$-NH-, where j is an integer from 1 to 5;

g is 0 or 1;

D is a drug moiety selected from:



and



,

or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; wherein the wavy lines indicate the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to linker;


the moiety Ab comprising at least one antigen binding site is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof; and

n is the ratio of the group [D-$(X)_b$-$(AA)_w$-$(T)_g$-(L)-] wherein L is as defined in formulas (IV), (V) or (VI) to the moiety Ab comprising at least one antigen binding site and is in the range from 3 to 5.


54. A drug conjugate according to claim 53, wherein the moiety Ab comprising at least one antigen binding site is selected from an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen binding fragment or an immunologically active portion thereof.

55. A drug conjugate according to claim 53, wherein the moiety Ab comprising at least one antigen binding site is Trastuzumab or an antigen binding fragment or an immunologically active portion thereof.


56. A drug conjugate according to claim 2, selected from the formulas (IV), (V), and (VI):



(IV)



(V)



(VI)


wherein:

R_{19} is C_2-C_6 alkylene ;

R_{30} is C_2-C_4 alkylene ;

M is C_1-C_3 alkylene (C_5-C_7 carbocyclo) ;

w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):



(III)

,

wherein R_{22} is isopropyl, R_{23} is selected from methyl and $-(CH_2)_3NHCONH_2$, and the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right);


X is an extending group selected from the group consisting of -COO-(C_2-C_4 alkylene)NH-, -COO-CH_2-phenylene-NH-, wherein said phenylene group may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C_2-C_4 alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -$COCH_2$NH-$COCH_2$-NH-, -COO-(C_2-C_4 alkylene)S-, and -COO-(C_2-C_4 alkylene)NHCO(C_1-C_3 alkylene)S- ;

b is 0 or 1, preferably 1;


wherein T is an extending group selected from -CO-(C_1-C_4-alkylene)-NH-, -CO-(C_1-C_4-alkylene)-[O-(C_2-C_4-alkylene)]$_j$-NH-, and -COO-(C_1-C_4-alkylene)-[O-(C_2-C_4-alkylene)]$_j$-NH-, where j is an integer from 1 to 5;

g is 0 or 1;

D is a drug moiety selected from:



and



;

or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; wherein the wavy lines indicate the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to linker;


the moiety Ab comprising at least one antigen binding site is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof; and

n is the ratio of the group [D-$(X)_b$-$(AA)_w$-$(T)_g$-(L)-] wherein L is as defined in formulas (IV), (V) or (VI) to the moiety comprising at least one antigen binding site and is in the range from 3 to 5.

57. A drug conjugate according to claim 56, wherein the moiety Ab comprising at least one antigen binding site is selected from an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof.

58. A drug conjugate according to claim 56, wherein the moiety Ab comprising at least one antigen binding site is Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof.

59. A drug conjugate according to claim 2, of formula (IV):




(IV)

;

wherein:

R_{19} is C_2-C_5-alkylene ;

w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):



(III)

,

wherein R_{22} is isopropyl, R_{23} is selected from methyl and $-(CH_2)_3NHCONH_2$, and the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right);


X is a $-COOCH_2$-phenylene-NH- group;

b is 1;

T is an extending group of formula $-CO-(C_1-C_4\text{ alkylene})-[O-(C_2-C_4\text{ alkylene})]_4-NH-$;

g is 0 or 1;

or of formula (V)



(V)

wherein M is -methyl-cyclohexylene-;


b is 1;

w is 0;

X is an extending group selected from $-(CH_2)_3S-$ and $-(CH_2)_3NHCO(CH_2)_2S-$

g is 0;

or of formula (VI)




(VI)

wherein R_{19} is $-C_2-C_5$ alkylene-;

R_{30} is $-C_3$ alkylene-;

w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):



(III) ;

wherein R_{22} is isopropyl, R_{23} is selected from methyl and $-(CH_2)_3NHCONH_2$, and the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to the drug moiety (the wavy line to the left) and to $(T)_g$ if any, or to the linker (the wavy line to the right); and


X is a $-COOCH_2$-phenylene-NH group;


b is 1;

T is an extending group of formula $-CO-(C_1-C_4\text{ alkylene})-[O-(C_2-C_4\text{-alkylene})]_4-NH-$;

g is 0 or 1;

D is a drug moiety selected from:





and ;

or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; wherein the wavy line indicates the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to the linker;


the moiety Ab comprising at least one antigen binding site is is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof; and

n is the ratio of the group $[D-(X)_b-(AA)_w-(T)_g-(L)-]$ wherein L is as defined in formula (IV) to the moiety comprising at least one antigen binding site and is in the range from 3 to 5, and preferably 4.


60. A drug conjugate according to claim 59, wherein the moiety Ab comprising at least one antigen binding site is selected from an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof.

61. A drug conjugate according to claim 59, wherein the moiety Ab comprising at least one antigen binding site is Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof.


6214. The ~~An~~ antibody drug conjugate according to claim 1, that is an antibody drug conjugate selected from the group consisting of:



,




,





,

and



,

wherein n is from 2 to 6, more preferably 3, 4, or 5 and each  and  is independently selected from is independently selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, and more preferably its is selected from an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof, particularly Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof~~.~~;

optionally

~~63. A drug conjugate according to claim 62,~~ wherein the moiety Ab comprising at least one antigen binding site is selected from an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof~~.~~; or

~~64. A drug conjugate according to claim 62,~~ wherein the moiety Ab comprising at least one antigen binding site is selected from Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof~~.~~;

or

~~65. A drug conjugate according to claim 64,~~ wherein the moiety Ab comprising at least one antigen binding site is selected from an anti-HER2 antibody such as Trastuzumab and anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof~~.~~;


or

~~66. A drug conjugate according to claim 64,~~ wherein the moiety Ab comprising at least one antigen binding site is selected from Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof.

~~67~~15. The ~~An~~ antibody drug conjugate according to any one of claims 1 to ~~66~~ 14 in isolated or purified form.

~~68~~16. A compound of formula D-$(X)_b$-$(AA)_w$-$(T)_g$-L_1 or of formula D-$(X)_b$-$(AA)_w$-$(T)_g$-H, wherein:

L_1 is a linker selected from the group of formulas consisting of:



wherein each of the the wavy lines indicates the point of covalent attachment to $(T)_g$ if any, or $(AA)_w$ if any, or to $(X)_b$ if any or to D;

G is selected from halo, -*O*-mesyl and -*O*-tosyl;

J is selected from halo, hydroxy, -*N*-succinimidoxy, -*O*-(4-nitrophenyl), -*O*-pentafluorophenyl, -*O*-tetrafluorophenyl and -O-C(O)-OR_{20};

R_{19} is selected from -C_1-C_{12} alkylene-, -C_3-C_8 carbocyclo, -O-(C_1-C_{12} alkylene), -C_6-C_{18} arylene in one or more rings which may optionally be substituted with one or more substituents R_x, -C_1-C_{12} alkylene-C_6-C_{18} arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, -C_6-C_{18} arylene-C_1-C_{12} alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, -C_1-C_{12} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{12} alkylene-, -C_5-C_{14} heterocyclo- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -C_1-C_{12} alkylene-(C_5-C_{14} heterocyclo)- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -(C_5-C_{14} heterocyclo)-C_1-C_{12} alkylene-, wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -$(OCH_2CH_2)_r$- and -CH_2-$(OCH_2CH_2)_r$-, wherein each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;

R_{20} is a C_1-C_{12} alkyl or an aryl group having from 6 to 18 carbon atoms in one or more aromatic rings, said aryl groups optionally being substituted with one or more substituents R_x;

r is an integer ranging from 1-10;

b is an integer of 0 or 1;

g is an integer of 0 or 1;

w is an integer ranging from 0 to 12;


wherein for compounds of formula D-(X-)$_b$(AA)$_w$-(T)$_g$-H, b+w+g≠0;

each of D, R_x, X, T, and AA is as defined in any one of claims 1 to ~~67~~15~~.~~;

optionally

~~69. A compound of formula D-(X)$_b$-(AA)$_w$-(T)$_g$-L$_1$- or of formula D-(X)$_b$-(AA)$_w$-(T)$_g$-H according to claim 68, wherein:~~

~~L$_1$ is a linker of formula:~~



~~wherein:~~

~~the wavy line indicates the point of covalent attachment to (T)$_g$ if any, or(AA)$_w$ if any, or to (X)$_b$ if any, or to D;~~

~~R_{19} is selected from C$_1$-C$_{12}$ alkylene , O-(C$_1$-C$_{12}$ alkylene), C$_6$-C$_{12}$ arylene in one or more rings which may optionally be substituted with one or more substituents R_x, C$_1$-C$_{12}$ alkylene-C$_6$-C$_{12}$ arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, C$_6$-C$_{12}$ arylene-C$_1$-C$_{12}$ alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x, C$_5$-C$_{12}$ heterocyclo- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, C$_1$-C$_{12}$ alkylene-(C$_5$-C$_{12}$ heterocyclo)- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, (C$_5$-C$_{12}$ heterocyclo)-C$_1$-C$_{12}$ alkylene- wherein said heterocyclo group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said group optionally being substituted with one or more substituents R_x, -(OCH$_2$CH$_2$)$_r$- and -CH$_2$-(OCH$_2$CH$_2$)$_r$-, wherein each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;~~

~~r is an integer ranging from 1-6;~~

~~b is an integer of 0 or 1;~~

~~g is an integer of 0 or 1;~~


~~w is an integer ranging from 0 to 12;~~

~~wherein for compounds of formula D-(X-)$_b$(AA)$_w$-(T)$_g$-H, b+w+g≠0;~~

~~each of D, R_x, X, AA, and T is as defined in any one of claims 1 to 67.~~

70. A compound of formula D-$(X)_b$-$(AA)_w$-$(T)_g$-L_1 or of formula D-$(X)_b$-$(AA)_w$-$(T)_g$-H according to claim 68 wherein:

L_1 is linker of formula:




;

wherein:

the wavy line indicates the point of covalent attachment to $(T)_g$ if any, or $(AA)_w$ if any, or to $(X)_b$ if any, or to D;

R_{19} is selected from C_1-C_8 alkylene, O-(C_1-C_8 alkylene), C_1-C_8 alkylene-C_6-C_{12} arylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x;and C_6-C_{12} arylene-C_1-C_8 alkylene- wherein the arylene group is in one or more rings which may optionally be substituted with one or more substituents R_x; wherein each of the above alkylene substituents whether alone or attached to another moiety the carbon chain may optionally be substituted by one or more substituents R_x;

$(AA)_w$ is of formula (II):



(II) ;

wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or D (the wavy line to the left) and to $(T)_g$ if any, or L_1 or to a hydrogen atom (the wavy line to the right);

wherein R_{21} is selected, at each occurrence, from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, $-(CH_2)_3NHCONH_2$, $-(CH_2)_4NH_2$, $-(CH_2)_3NHC(=NH)NH_2$ and $-(CH_2)_4NHC(=NH)NH_2$; and w is an integer from 0 to 6;

X is an extending group selected from the group consisting of

-COO-(C_2-C_4 alkylene)NH, -COO-CH_2-phenylene-NH, wherein said phenylene group may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C_2-C_4 alkylene)NH-COO-CH_2-(phenylene which may optionally be substituted with from one to four substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH, -$COCH_2$NH-$COCH_2$-NH, -COO-(C_2-C_4 alkylene)S, and -COO-(C_2-C_4 alkylene)-NHCO(C_1-C_3 alkylene)S, or


T is an extending group selected from -CO-(C_1-C_4 alkylene)-NH; -CO-(C_1-C_4 alkylene)-[O-(C_2-C_4 alkylene)]$_j$-NH- and -COO-(C_1-C_4 alkylene)-[O-(C_2-C_4 alkylene)]$_j$-NH, where j is an integer from 1 to 10;

b is 0 or 1;

g is 0 or 1;

wherein for compounds of formula D-(X-)$_b$(AA)$_w$-(T)$_g$-H, b+w+g≠0; and

D is a drug moiety of formula **(III)**, or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof



(III)

wherein the wavy line of **(III)** indicate the point of covalent attachment to (X)$_b$ if any, or (AA)$_w$ if any, or to (T)$_g$ if any, or to L$_1$;

R$_1$ is -OH or -CN;

R$_2$ is a -C(=O)R$_a$ group, wherein R$_a$ is selected from hydrogen and substituted or unsubstituted C$_1$-C$_6$ alkyl, wherein the optional substituents are one or more substituents R$_x$;


R$_3$ is hydrogen or a -OR$_b$ group wherein R$_b$ is a substituted or unsubstituted C$_1$-C$_6$ alkyl group, wherein the optional substituents are one or more substituents R$_x$;

Y is -NH- or -O-; and

R$_4$ is hydrogen, -CH$_2$OH, or -CH$_2$NH$_2$.

71. A compound of formula D-(X)$_b$-(AA)$_w$-(T)$_g$-L$_1$ or of formula D-(X)$_b$-(AA)$_w$-(T)$_g$-H according to claim 68 wherein:

L$_1$ is a group of formula:




,

wherein:

the wavy line indicates the point of covalent attachment to (T)$_g$ if any, or (AA)$_w$ if any, or to (X)$_b$ if any or to D;

R_{19} is selected from C_1-C_6 alkylene , phenylene C_1-C_6 alkylene- wherein the phenylene group may optionally be substituted with one or more substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, wherein each of the above alkylene substituents whether alone or attached to another moiety in the carbon chain may optionally be substituted by one or more substituents R_x selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, aryl groups having from 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups, and preferably R_{19} is a C_1-C_6 alkylene group;

w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):



(III)

wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or D (the wavy line to the left) and to $(T)_g$ if any, or L_1 or to a hydrogen atom (the wavy line to the right);

R_{22} is selected from methyl, benzyl, isopropyl, *sec*-butyl and indolylmethyl;

R_{23} is selected from methyl, $-(CH_2)_4NH_2$, $-(CH_2)_3NHCONH_2$ and $-(CH_2)_3NHC(=NH)NH_2$;

X is an extending group selected from

$-COO-CH_2$-phenylene-NH, $-COO(CH_2)_3)NHCOO-CH_2$-phenylene-NH, $-COO-(CH_2)_3NH-$, $-COO(CH_2)_3-S-$, and $-COO-(CH_2)_3NHCO-(CH_2)_2S-$; or


wherein T is an extending group selected from $-CO-(C_1-C_4$ alkylene)-NH-, $-CO-(C_1-C_4$ alkylene)-$[O-(C_2-C_4$ alkylene)$]_j$-NH-, and $-COO-(C_1-C_4$ alkylene)-$[O-(C_2-C_4$ alkylene)$]_j$-NH-, where j is an integer from 1 to 5;

b is an integer of 0 or 1;

g is 0 or 1;

wherein for compounds of formula $D-(X)_b-(AA)_w-(T)_g-H$, $b+w+g \neq 0$; and

or D is a drug moiety of formula **(III)**, or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof:



~~(III)~~

~~wherein the wavy line of **(III)** indicate the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to L_1;~~

~~R_1 is CN or OH;~~

~~R_2 is acetyl;~~


~~R_3 is hydrogen or methoxy, preferably methoxy;~~

~~Y is –NH– or –O–; and~~

~~R_4 is hydrogen, $-CH_2OH$, or $-CH_2NH_2$.~~

~~72. A compound of formula $D-(X)_b-(AA)_w-(T)_g-L_1$ or of formula $D-(X)_b-(AA)_w-(T)_g-H$ according to claim 68 wherein:~~

~~L_1 is a linker of formula:~~




~~wherein:~~

~~the wavy line indicates the point of covalent attachment to $(T)_g$ if any, or $(AA)_w$ if any, or to $(X)_b$, if any or to (D);~~

~~R_{19} is C_2-C_6 alkylene;~~

~~w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):~~



(III)

R_{22} is isopropyl, R_{23} is selected to methyl and $-(CH_2)_3NHCONH_2$, wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or D (the wavy line to the left) and to $(T)_g$ if any, or L_1 or to a hydrogen atom (the wavy line to the right);

X is an extending group selected from $-COO-CH_2$-phenylene-NH-, $-COO(CH_2)_3NHCOO-CH_2$-phenylene-NH-, $-COO-(CH_2)_3)NH-$, $-COO(CH_2)_3-S-$, and $-COO-(CH_2)_3NHCO-(CH_2)_2S-$;


wherein T is an extending group selected from $-CO-(C_1-C_4$ alkylene)-NH-, $-CO-(C_1-C_4$ alkylene)-$[O-(C_2-C_4$ alkylene)$]_j$-NH-, and $-COO-(C_1-C_4$ alkylene)-$[O-(C_2-C_4$ alkylene)$]_j$-NH-, where j is an integer from 1 to 5;

b is 0 or 1;


g is 0 or 1;

wherein for compounds of formula $D-(X-)_b(AA)_w-(T)_g-H$, $b+w+g\neq0$; and

D is a drug selected from:




and



, or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; wherein the wavy line indicates the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to L_1.

73. A compound of formula $D-(X)_b-(AA)_w-(T)_g-L_1$ or of formula $D-(X)_b-(AA)_w-(T)_g-H$ according to claim 68 wherein:

L_1 is a group of formula:




,

wherein:

the wavy line indicates the point of covalent attachment to $(T)_g$ if any, or $(AA)_w$ if any, or to $(X)_b$ if any, or to D;

R_{19} is $-C_2-C_5$-alkylene-;

w is 0 or 2, and where w is 2, then $(AA)_w$ is of formula (III):



(III)

,

~~wherein R_{22} is isopropyl, R_{23} is selected from methyl and $-(CH_2)_3NHCONH_2$, wherein the wavy lines indicate the point of covalent attachments to $(X)_b$ if any, or to D (the wavy line to the left) and to $(T)_g$ if any, or L_1 or to a hydrogen atom (the wavy line to the right);~~

~~X is a $-COO-CH_2-$phenylene$-NH-$ group;~~


~~T is a $-CO-(CH_2)_2-[O-(CH_2)_2]_4-NH-$ group;~~

~~b is an integer of 0 or 1;~~


~~g is 0 or 1;~~

~~wherein for compounds of formula $D-(X-)_b(AA)_w-(T)_g-H$, $b+w+g \neq 0$; and~~

~~D is a drug moiety selected from:~~




~~and~~




,

~~or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; wherein the wavy line indicates the point of covalent attachment to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or to L_1.~~

~~74. A~~ wherein the compound of formula $D-X-(AA)_w-(T)_g-L_1$ ~~according to any one of claims 68 to 73~~ is selected from:



and



~~75~~17. ~~A~~ The compound of claim 16 of formula D-$(X)_b$-$(AA)_w$-$(T)_g$-L_1 or of formula D-$(X)_b$-$(AA)_w$-$(T)_g$-H, wherein each of D, X, AA, T, L_1, b, g and w are as defined in any one of claims 1 to ~~66~~15; but further wherein if the compound is a compound of formula D-$(X)_b$-$(AA)_w$-$(T)_g$-H then b+w+g~~≠~~0.

~~76~~18. ~~A~~ The drug conjugate according to any one of claims 1 to ~~75~~17, wherein b+g+w is not 0~~.~~;

or

~~77. A drug conjugate according to any one of claims 1 to 76,~~ wherein b+w is not 0~~.~~;

or

~~78. A drug conjugate according to any one of claims 1 to 77,~~ wherein when w is not 0, then b is 1

~~.~~or

~~79. A drug conjugate according to any one of claims 1 to 77,~~ wherein when w is 0, then b is 1.

~~80~~19. ~~A~~ The drug conjugate according to any preceding claim, wherein, unless otherwise defined, if substituted, substituted groups are substituted with one or more substituents R_x that are independently selected from the group consisting of C_1-C_{12} alkyl groups which may be optionally substituted with at least one group R_y, C_2-C_{12} alkenyl groups which may be optionally substituted with at least one group R_y, C_2-C_{12} alkynyl groups which may be optionally substituted with at least one group R_y, halogen atoms, oxo groups, thio groups, cyano groups, nitro groups, OR_y, $OCOR_y$, $OCOOR_y$, COR_y, $COOR_y$, $OCONR_yR_z$, $CONR_yR_z$, $S(O)R_y$, SO_2R_y, $P(O)(R_y)OR_z$, NR_yR_z, NR_yCOR_z, $NR_yC(=O)NR_yR_z$, $NR_yC(=NR_y)NR_yR_z$, aryl groups having from 6 to 18 carbon atoms in one or more rings which may optionally be substituted with one or more substituents which may be the same or different selected from the group consisting of R_y, OR_y, $OCOR_y$, $OCOOR_y$, NR_yR_z, NR_yCOR_z, and $NR_yC(=NR_y)NR_yR_z$, aralkyl groups comprising an alkyl group having from 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, aralkyloxy groups comprising an alkoxy group having from 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, and a 5- to 14- membered saturated or unsaturated heterocyclic group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said heterocyclic group optionally being substituted with one or more substituents R_y, and where there is more than one optional substituents on any given group the optional substituents R_y may be the same or different;

each R_y and R_z is independently selected from the group consisting of hydrogen, C_1-C_{12} alkyl groups, C_1-C_{12} alkyl groups that are substituted with at least one halogen atom, aralkyl groups comprising a C_1-C_{12} alkyl group that is substituted with an aryl group having from 6 to 18 carbon atoms in one or more rings and heterocycloalkyl groups comprising a C_1-C_{12} alkyl group that is substituted with a 5- to 14- membered saturated or unsaturated heterocyclic group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s).

~~81~~20. A process of manufacturing an antibody drug conjugate, comprising using ~~A~~ a drug moiety as described in any one of claims 1 to ~~21~~5 as a payload~~, for use as a payload in an antibody drug conjugate~~.

~~82. Use of a drug moiety as described in any one of claims 1 to 21, in the manufacture of a antibody drug conjugate.~~

~~83~~21. A drug conjugate according to any one of claims 1 to ~~67~~15, for use as a medicament.

~~84. A drug conjugate according to any one of claims 1 to 67 for use in the treatment of cancer, and more preferably a cancer selected from lung cancer including NSCLC, gastric cancer, colorectal cancer, breast cancer, pancreas carcinoma, endometrial cancer, bladder cancer, cervical cancer, esophageal cancer, gallbladder cancer, uterine cancer, salivary duct cancer, ovarian cancer, kidney cancer, leukaemia, multiple myeloma, and lymphoma.~~

~~85. A drug conjugate according to claim 84, wherein the cancer is a HER2 positive cancer, preferably HER2 positive lung cancer including HER2 positive NSCLC, HER2 positive gastric cancer, HER2 positive colorectal cancer, HER2 positive breast cancer, HER2 positive pancreas carcinoma, HER2 positive endometrial cancer, HER2 positive bladder cancer, HER2 positive cervical cancer, HER2 positive esophageal cancer, HER2 positive gallbladder cancer, HER2 positive uterine cancer, HER2 positive salivary duct cancer and HER2 positive ovarian cancer, particularly preferably HER2 positive breast cancer, HER2 positive ovarian cancer and HER2 positive gastric cancer, most preferably HER2 positive breast cancer.~~

~~86~~22. A pharmaceutical composition comprising a drug conjugate according to any one of claims 1 to ~~67~~15 and a pharmaceutically acceptable carrier.

~~87. A method for the prevention or treatment of cancer comprising administering an effective amount of a drug conjugate according to any one of claims 1 to 67 to a patient in need thereof.~~

~~88. A method for the treatment of cancer according to claim 84, wherein the cancer is selected from lung cancer including NSCLC, gastric cancer, colorectal cancer, breast cancer, pancreas carcinoma, endometrial cancer, bladder cancer, cervical cancer, esophageal cancer, gallbladder cancer, uterine cancer, salivary duct cancer, ovarian cancer, kidney cancer, leukaemia, multiple myeloma, and lymphoma.~~

~~89. The method according to claim 88, wherein the cancer is a HER2 positive cancer, preferably HER2 positive lung cancer including HER2 positive NSCLC, HER2 positive gastric cancer, HER2 positive colorectal cancer, HER2 positive breast cancer, HER2 positive pancreas carcinoma, HER2 positive endometrial cancer, HER2 positive bladder cancer, HER2 positive cervical cancer, HER2 positive esophageal cancer, HER2 positive gallbladder cancer, HER2 positive uterine cancer, HER2 positive salivary duct cancer and HER2 positive ovarian cancer, particularly preferably HER2 positive breast cancer, HER2 positive ovarian cancer and HER2 positive gastric cancer, most preferably HER2 positive breast cancer.~~

~~90~~23. Use of a drug conjugate according to any one of claims 1 to ~~67~~ 15 in the ~~preparation~~ manufacture of a medicament for the treatment of cancer, preferably a cancer selected from

lung cancer including NSCLC, colorectal cancer, breast cancer, pancreas carcinoma, endometrial cancer, bladder cancer, cervical cancer, esophageal cancer, gallbladder cancer, uterine cancer, salivary duct cancer, ovarian cancer, kidney cancer, leukaemia, multiple myeloma, and lymphoma~~.~~; optionally

~~91. The use according to claim 90,~~ wherein the cancer is a HER2 positive cancer, preferably HER2 positive lung cancer including HER2 positive NSCLC, HER2 positive gastric cancer, HER2 positive colorectal cancer, HER2 positive breast cancer, HER2 positive pancreas carcinoma, HER2 positive endometrial cancer, HER2 positive bladder cancer, HER2 positive cervical cancer, HER2 positive esophageal cancer, HER2 positive gallbladder cancer, HER2 positive uterine cancer, HER2 positive salivary duct cancer and HER2 positive ovarian cancer, particularly preferably HER2 positive breast cancer, HER2 positive ovarian cancer and HER2 positive gastric cancer, most preferably HER2 positive breast cancer.

~~92. A kit comprising a therapeutically effective amount of a drug conjugate according to any one of claims 1 to 67 and a pharmaceutically acceptable carrier.~~

~~93. The kit according to claim 87 for use in the treatment of cancer, and more preferably a cancer selected from lung cancer including NSCLC, colorectal cancer, breast cancer, pancreas carcinoma, endometrial cancer, bladder cancer, cervical cancer, esophageal cancer, gallbladder cancer, uterine cancer, salivary duct cancer, ovarian cancer, kidney cancer, leukaemia, multiple myeloma, and lymphoma.~~


~~94. The kit according to claim 93, wherein the cancer is a HER2 positive cancer, preferably HER2 positive lung cancer including HER2 positive NSCLC, HER2 positive gastric cancer, HER2 positive colorectal cancer, HER2 positive breast cancer, HER2 positive pancreas carcinoma, HER2 positive endometrial cancer, HER2 positive bladder cancer, HER2 positive cervical cancer, HER2 positive esophageal cancer, HER2 positive gallbladder cancer, HER2 positive uterine cancer, HER2 positive salivary duct cancer and HER2 positive ovarian cancer, particularly preferably HER2 positive breast cancer, HER2 positive ovarian cancer and HER2 positive gastric cancer, most preferably HER2 positive breast cancer.~~

~~95~~24. The drug conjugate according to any one of claims 1 to ~~67~~15, wherein n is in the range of from 1-12, 1-8, 3-8, 3-6, 3-5, 1, 2, 3, 4, 5 or 6; preferably 3, 4 or 5 or more preferably 4.


~~96~~25. A process for the preparation of a drug antibody conjugate according to any one of claims 1 to ~~67~~ 15 comprising conjugating a moiety Ab comprising at least one antigen binding site and a drug D, Ab and D being as defined in any one of claims 1 to ~~67~~15~~.~~;

optionally wherein

~~97. A process according to claim 96 for~~ the preparation of a drug antibody conjugate of formula (G) or (G'):




(G)




(G')

said process comprising the following steps:


(i) reacting a drug D-H of formula **(IH)**-H:



wherein the substituents in the definitions of (**IH**)-H are as defined in any one of claims 1 to ~~67~~15, with a compound of formula (D') or (E):




(D')




(E)

to give a compound of formula (F) or (F'), respectively:




(F)




(F')

(ii) partial reduction of one or more disulfide bonds in the antibody to be conjugated to give a reduced antibody Ab-SH having free thiol groups:




; and

(iii) reaction of the partially reduced antibody Ab-SH having free thiol groups with the compound of formula (F) or (F') produced in step (i) to give the desired drug antibody conjugate of formula (G) or (G') respectively:




(G)




(G’).

98. A process according to claim 97, wherein the antibody is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof which is partially reduced in step (ii) using tris[2-carboxyethyl]phosphine hydrochloride, preferably the antibody is selected from an anti-HER2 antibody such as Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof which is partially reduced in step (ii) using tris[2-carboxyethyl]phosphine hydrochloride and most preferably it is Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof which is partially reduced in step (ii) using tris[2-carboxyethyl]phosphine hydrochloride.

99. A process according to claim 96 for the preparation of a drug antibody conjugate of formula (W) or (W’):



(W)




(W’)

said process comprising the following steps:


(i) reacting the antibody with 2-iminothiolane hydrochloride (Traut´s reagent) to give a thiol-activated antibody:



(ii) reacting the thiol-activated antibody with the compound of formula (F) or (F’), to give the desired drug antibody conjugate of formula (W) or (W’), respectively.




(W)




(W')

100. A process according to claim 99, wherein the antibody is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, an anti-HER2 antibody such as Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, preferably the antibody is selected from an anti-HER2 antibody such as Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof and most preferably it is Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof.

101. A process according to claim 96 for the preparation of a drug-antibody conjugate of formula (O) or (P):



(O)




(P)


said process comprising the following steps:

(i) either:

(a) reacting a drug (D-H) of formula formula **(III)** H:




~~wherein the substituents in the definitions of **(III)** H are as defined in any one of claims 1 to 67, with a compound of formula X_2-C(O)-X_1 wherein X_1 and X_2 are leaving groups to give a compound of formula (B):~~



(B)

~~and the point of attachment of the $(C=O)X_1$ moiety is the free NH_2 group of the compound of formula D-H, or~~

~~(b) reacting said drug (D-H) of formula **(III)** H as defined above with 4-nitrophenylchloroformate to give a compound of formula (J):~~




(J)

~~and the point of attachment of the (4-nitrophenyl) O-CO- group is the same as that for the X_1(CO) moiety in (a) above;~~


~~(ii) either:~~

~~(c) reacting the compound of formula (B) produced in step (i) with a hydroxy compound of formula HO-$(CH_2)_{1-6}$NHProt^{NH} and removing the Prot^{NH} group from the coupled compound to give a compound of formula (C):~~



(C)


~~and then reacting the resulting compound of formula (C) with a compound of formula Me-S-S-$(CH_2)_{1-3}$-CO_2H to give a compound of formula (K)~~



(K)

, or

(d) reacting the compound (J) produced in step (i) with a compound of formula HO-$(CH_2)_{1-3}$SProt^{SH} and removing the Prot^{SH} group from the coupled compound to give a compound of formula (L):




(L)

(iii) reacting (K) or (L) produced in step (ii) with dithiothreitol under disulfide reducing conditions to give compounds of formula (M) and (N) respectively:




(M) (N)


(iv) reacting the antibody to be conjugated with succininimidyl 4 (*N*-maleimidomethyl)cyclohexane 1 carboxylate to derivatise said antibody at one or more lysine groups with a succininimidyl 4 (*N* maleimidomethyl)cyclohexane 1 carbonyl group:



(v) reacting the derivatised antibody produced in step (iv) with either (M) or (N) produced in step (iii) to give the desired drug antibody conjugate of formula (O) or (P):



(O)



(P)


~~102. A process according to claim 101, wherein the compound of formula X_2-C(O)-X_1 is 1,1'-carbonyldiimidazole.~~

~~103. A process according to claim 101 or claim 102, wherein the hydroxy compound reacted with the compound of formula (B) is preferably HO-$(CH_2)_{2-4}$-NHProtNH, and preferably HO-$(CH_2)_3$-NHProt^{NH}.~~

~~104. A process according to any one of claims 101 to 102, wherein the compound reacted with the compound of formula (C) to give the compound of formula (K) is 3-(methyldisulfanyl)propanoic acid.~~

~~105. A process according to claim 101, wherein the compound of formula HO-$(CH_2)_{1-3}$SProt^{SH} that is reacted with a compound of formula (J) to give a compound of formula (L) is HO-$(CH_2)_3$SProt^{SH}.~~

~~106~~26. A compound of formula **(IA)**



(IA)

wherein:

Y is -NH- or -O-;

R_1 is -OH or -CN;

R_2 is a -C(=O)R_a group;

R_3 is hydrogen or a OR_b group;

R_4 is selected from hydrogen, $-CH_2OH$, $-CH_2OC(=O)R_c$, $-CH_2NH_2$ and $-CH_2NHProt^{NH}$;

R_a is selected from hydrogen, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl;

R_b is selected from substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl;

R_c is selected from substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl; and

$Prot^{NH}$ is a protecting group for amino;

with the proviso that when R_4 is hydrogen, then Y is -O-.

~~107. A compound according to claim 106, wherein R_2 is a $-C(=O)R_a$ group where R_a is substituted or unsubstituted C_1-C_6 alkyl.~~

~~108. A compound according to claim 107, wherein R_2 is acetyl.~~

~~109. A compound according to any one of claims 106 to 108, wherein R_3 is selected from hydrogen and OR_b, wherein R_b is substituted or unsubstituted C_1-C_6 alkyl.~~

~~110. A compound according to claim 109, wherein R_3 is selected from hydrogen and methoxy.~~

~~111. A compound according to any of claims 106 to 110, wherein R_4 is selected from hydrogen, $-CH_2OH$, $-CH_2OC(=O)R_c$ and $-CH_2NH_2$, where R_c is substituted or unsubstituted C_1-C_6 alkyl.~~

~~112. A compound according to claim 111, where R_4 is selected from hydrogen, $-CH_2OH$ and $-CH_2NH_2$.~~

~~113. A compound according to claim 112, where R_4 is selected from hydrogen and $-CH_2OH$.~~

~~114. A compound according to claim 113, where R_4 is hydrogen.~~

~~115. A compound according to any one of claims 106 to 114, wherein R_1 is -CN.~~

~~116. A compound according to any one of claims 106 to 114, wherein R_1 is -OH.~~

~~117. A compound according to any one of claims 106 to 116, wherein Y is -NH-.~~

~~118. A compound according to any one of claims 106 to 116, wherein Y is -O-.~~

~~119. A compound according to any one of claims 106 to 118, wherein, if substituted, substituted groups are substituted with one or more substituents R_x that are independently selected from the group consisting of C_1-C_{12} alkyl groups which may be optionally substituted with at least one group R_y, C_2-C_{12} alkenyl groups which may be optionally substituted with at least one group R_y, C_2-C_{12} alkynyl groups which may be optionally substituted with at least one group R_y, halogen atoms, oxo groups, thio groups, cyano groups, nitro groups, OR_y, $OCOR_y$, $OCOOR_y$, COR_y, $COOR_y$, $OCONR_yR_z$, $CONR_yR_z$, $S(O)R_y$, SO_2R_y, $P(O)(R_y)OR_z$, NR_yR_z, NR_yCOR_z, $NR_yC(=O)NR_yR_z$, $NR_yC(=NR_y)NR_yR_z$, aryl groups having from 6 to 18 carbon atoms in one or more rings which may optionally be substituted with one or more~~

substituents which may be the same or different selected from the group consisting of R_y, OR_y, $OCOR_y$, $OCOOR_y$, NR_yR_z, NR_yCOR_z, and $NR_yC(=NR_y)NR_yR_z$, aralkyl groups comprising an alkyl group having from 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, aralkyloxy groups comprising an alkoxy group having from 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, and a 5- to 14- membered saturated or unsaturated heterocyclic group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s), said heterocyclic group optionally being substituted with one or more substituents R_y, and where there is more than one optional substituents on any given group the optional substituents R_y may be the same or different;

each R_y and R_z is independently selected from the group consisting of hydrogen, C_1-C_{12} alkyl groups, C_1-C_{12} alkyl groups that are substituted with at least one halogen atom, aralkyl groups comprising a C_1-C_{12} alkyl group that is substituted with an aryl group having from 6 to 18 carbon atoms in one or more rings and heterocycloalkyl groups comprising a C_1-C_{12} alkyl group that is substituted with a 5- to 14- membered saturated or unsaturated heterocyclic group having one or more rings and comprising at least one oxygen, nitrogen or sulphur atom in said ring(s).